# Fibrosis-4 index as a predictor of all-cause and cardiovascular mortality in patients with chronic kidney disease

**Authors:** Zheng-Yang Zhu, Ke-Jun Ren, Xiao-Wei Duan, Xu-Lei Hu, Yong Lv, Dong Wang, Hua Jin, Lei Zhang

PMC · DOI: 10.1371/journal.pone.0329315 · PLOS One · 2025-08-01

## TL;DR

The Fibrosis-4 (FIB4) index is shown to predict all-cause and cardiovascular mortality in patients with chronic kidney disease.

## Contribution

This is the first study to demonstrate the FIB4 index as an independent predictor of mortality in CKD patients.

## Key findings

- Each 1-unit increase in FIB4 index is associated with a 34% higher risk of all-cause and cardiovascular mortality.
- Nonlinear threshold effects were identified at FIB4 values of 1.84 and 1.74 for all-cause and CVD mortality, respectively.
- The FIB4 index showed strong predictive performance with AUC values of 0.799 and 0.801 for all-cause and CVD mortality.

## Abstract

This study utilized data from the National Health and Nutrition Examination Survey (NHANES) 2005–2020 (n = 28,231, including 4,907 chronic kidney disease (CKD) patients) with weighted analyses and, through variance inflation factor (VIF) assessment to verify covariate selection, supported model validity, to demonstrate for the first time that the Fibrosis-4 (FIB4) index serves as an independent predictor of all-cause and cardiovascular disease (CVD)-related mortality in CKD patients. Weighted logistic regression confirmed FIB4 index as a significant independent predictor of CKD risk (fully adjusted odds ratios (OR) 1.85, 95% confidence interval (CI) 1.64–2.08), with strong dose-response gradient (Q4 OR 3.51–6.02). Multivariable Cox proportional hazards regression models revealed that each 1-unit increase in the FIB4 index was associated with a 34% elevated risk of all-cause mortality (hazard ratio (HR) = 1.34, 95%CI: 1.27–1.41, p < 0.001) and a 34% increased risk of CVD mortality (HR = 1.34, 95% CI: 1.24–1.44, p < 0.001). Restricted cubic spline (RCS) analysis identified nonlinear threshold effects at inflection points of 1.84 (all-cause mortality) and 1.74 (CVD mortality), with mortality risks escalating sharply beyond these thresholds (all-cause HR = 2.57; CVD HR = 2.85). Receiver operating characteristic (ROC) curve analysis demonstrated robust predictive performance (area under the curve (AUC): 0.799 for all-cause mortality; 0.801 for CVD mortality). Subgroup analyses highlighted heightened risks among non-Hispanic Black individuals, older adults, and those with low physical activity. Mediation analysis indicated that neutrophil-to-lymphocyte ratio (NLR) mediated 5.48% of the FIB4–all-cause mortality association and 5.83% of the CVD mortality association, though direct effects predominated (94.52% and 94.17%, respectively). These findings establish the FIB4 index as a practical, evidence-based tool for risk stratification in CKD patients, offering critical insights for personalized clinical management.

## Linked entities

- **Diseases:** chronic kidney disease (MONDO:0005300), cardiovascular disease (MONDO:0004995)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, FGF23 (fibroblast growth factor 23) [NCBI Gene 8074] {aka ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, MB (myoglobin) [NCBI Gene 4151] {aka MYOSB, PVALB}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** uremic cardiomyopathy (MESH:D009202), Death (MESH:D003643), metabolic disturbances (MESH:D024821), Kidney Disease (MESH:D007674), fibrotic organ damage (MESH:D000092124), chronic (MESH:D002908), endothelial dysfunction (MESH:D014652), atherosclerosis (MESH:D050197), uremic (MESH:D006463), arterial stiffness (MESH:C566112), advanced (MESH:D020178), CKD (MESH:D012080), myocardial infarction (MESH:D009203), dysfunction (MESH:D006331), coronary artery disease (MESH:D003324), stroke (MESH:D020521), Diabetes (MESH:D003920), viral hepatitis (MESH:D014777), CVD (MESH:D002318), metabolic (MESH:D008659), Hypertension (MESH:D006973), multi-organ dysfunction (MESH:D009102), metabolic toxicity (MESH:D065606), chronic inflammation (MESH:D007249), hepatogenic injury (MESH:D014947), cardio-renal-hepatic deterioration (MESH:D059347), hyperglycemia (MESH:D006943), angina (MESH:D000787), vascular calcification (MESH:D061205), NLR (MESH:D015467), drug toxicity (MESH:D064420), muscle injury (MESH:D009135), heart failure (MESH:D006333), Fibrosis (MESH:D005355), metabolic dysregulation (MESH:D021081), liver disease (MESH:D008107), chronic kidney disease (MESH:D051436), hepatic fibrosis (MESH:D008103)
- **Chemicals:** alcohol (MESH:D000438), TG (MESH:D014280), glucose (MESH:D005947), UA (MESH:D014527), creatinine (MESH:D003404)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12316213/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12316213/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12316213/full.md

---
Source: https://tomesphere.com/paper/PMC12316213